• The follow on study involves assessing of PF708 vs Forteo in 102 patients including 52 with osteoporosis and 50 with caregivers
• The study demonstrated PF708 had fewer or equal user errors showing 33% and 17 % of critical tasks respectively further concluded that the study data of user interface of the FDA-approved PF708 product is noninferior to that of Forteo
• PF708 is a mAb approved by the US FDA for treatment of osteoporosis in certain patients at high risk for fracture and is filled with RMA under biosimilar pathway referencing Forsteo

Click here to­ read full press release/ article | Ref: Pfizer | Image: Pharma World